by on March 4, 2024
Cancer begins with genetic changes inside cells that cause them to grow and divide uncontrollably. As tumors grow, cells are continuously dying off and releasing DNA into the bloodstream. This circulating cell-free DNA (cfDNA) contains genetic mutations from the original tumor. Recent advances have enabled the detection and analysis of this circulating tumor DNA (ctDNA) and opened up new possibilities for cancer management. What is ctDNA? Circulating tumor DNA, also known as liquid biopsy,...
12 views 0 likes
by on February 23, 2024
The circulating cell-free tumor DNA market plays a vital role as they provide non-invasive options for cancer diagnosis and prognosis. With advantages such as ease of procurement through blood draws and ability to detect cancer across all stages, demand for circulating cell-free tumor DNA is increasing globally. The Global circulating cell-free tumor DNA Market is estimated to be valued at US$ 7.03 Mn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2024 to 2030.   ...
15 views 0 likes
by on January 22, 2024
  Circulating cell-free tumor DNA, also known as blood-based biomarkers, are useful tools in cancer diagnosis and treatment monitoring. They provide genomic information that helps in understanding the molecular profiles of tumors and detecting cancer early. Cell-free DNA can efficiently monitor treatment response and detect relapse or resistance to therapy. The global circulating cell-free tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of...
19 views 0 likes